Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Locally Advanced
100%
Chemoradiation
100%
Larynx Cancer
100%
Organ Preservation
75%
Long-term Survival
50%
Preservation Rate
50%
Laryngeal Cancer
50%
Treatment Strategy
25%
Overall Survival
25%
Multi-institutional Study
25%
Negative Impact
25%
Cisplatin
25%
Accruals
25%
Overall Survival Rate
25%
Laryngectomy
25%
Patient Outcomes
25%
Total Dose
25%
Tracheostomy
25%
High-dose Radiation
25%
Single Patient
25%
Pembrolizumab
25%
Long Follow-up
25%
Definitive Chemoradiation
25%
Laryngeal Squamous Cell Carcinoma
25%
Laryngeal Edema
25%
Organ-preserving Strategies
25%
Poorly Controlled Diabetes
25%
Patient Follow-up
25%
Medicine and Dentistry
Chemoradiotherapy
100%
Immunotherapy
100%
Laryngeal Cancer
100%
Overall Survival
40%
Long Term Survival
40%
Cisplatin
40%
Drug Megadose
20%
Diabetes
20%
Survival Rate
20%
Arm
20%
Tracheostomy
20%
Larynx
20%
Neutron Capture Therapy
20%
Laryngectomy
20%
Larynx Squamous Cell Carcinoma
20%
Larynx Edema
20%
Pembrolizumab
20%
Median Follow Up
20%
Immunology and Microbiology
Immunotherapy
100%
Larynx
100%
Overall Survival
66%
Long Term Survival
66%
Arm
33%
Survival Rate
33%
Drug Megadose
33%
Squamous Cell
33%
Pembrolizumab
33%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Chemoradiation Therapy
100%
Larynx Cancer
100%
Overall Survival
40%
Cisplatin
40%
Long Term Survival
40%
Survival Rate
20%
Larynx Edema
20%
Pembrolizumab
20%